[go: up one dir, main page]

ES2029805T3 - Procedimiento para preparar un producto que contiene amantadina y selegilina en asociacion sinergica. - Google Patents

Procedimiento para preparar un producto que contiene amantadina y selegilina en asociacion sinergica.

Info

Publication number
ES2029805T3
ES2029805T3 ES198787104818T ES87104818T ES2029805T3 ES 2029805 T3 ES2029805 T3 ES 2029805T3 ES 198787104818 T ES198787104818 T ES 198787104818T ES 87104818 T ES87104818 T ES 87104818T ES 2029805 T3 ES2029805 T3 ES 2029805T3
Authority
ES
Spain
Prior art keywords
selegiline
preparing
procedure
product containing
containing amantadine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787104818T
Other languages
English (en)
Inventor
Dirk Dr. Reischig
Helmut Dr. Hettche
Wolfgang Dr. Brade
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asta Medica GmbH
Original Assignee
Asta Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Pharma AG filed Critical Asta Pharma AG
Application granted granted Critical
Publication of ES2029805T3 publication Critical patent/ES2029805T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

MEDICAMENTOS CON ACCION SINERGICA, QUE CONTIENEN UNA COMBINACION DE AMANTADINA Y SELEGILINA.
ES198787104818T 1986-04-16 1987-04-01 Procedimiento para preparar un producto que contiene amantadina y selegilina en asociacion sinergica. Expired - Lifetime ES2029805T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3612702 1986-04-16

Publications (1)

Publication Number Publication Date
ES2029805T3 true ES2029805T3 (es) 1992-10-01

Family

ID=6298731

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787104818T Expired - Lifetime ES2029805T3 (es) 1986-04-16 1987-04-01 Procedimiento para preparar un producto que contiene amantadina y selegilina en asociacion sinergica.

Country Status (19)

Country Link
US (1) US4812481A (es)
EP (1) EP0241809B1 (es)
JP (1) JPS62249923A (es)
AT (1) ATE55245T1 (es)
AU (1) AU598533B2 (es)
CA (1) CA1298200C (es)
DD (1) DD259352A5 (es)
DE (1) DE3764144D1 (es)
DK (1) DK168514B1 (es)
ES (1) ES2029805T3 (es)
FI (1) FI871668A7 (es)
GR (1) GR3000707T3 (es)
HU (1) HU197840B (es)
IE (1) IE60245B1 (es)
IL (1) IL82216A0 (es)
NO (1) NO871581L (es)
PL (1) PL265152A1 (es)
PT (1) PT84684B (es)
ZA (1) ZA872690B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US4861800A (en) * 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
GB8807504D0 (en) * 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
HU208484B (en) * 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
WO1992000066A1 (en) * 1990-06-25 1992-01-09 The Du Pont Merck Pharmaceutical Company Amantadine hydrochloride suspension with enhanced dissolution characteristics for use in soft gelatin capsules
US5175002A (en) * 1991-10-02 1992-12-29 Du Pont Merck Pharmaceutical Company Amantadine hydrochloride syspension with enhanced dissolution characteristics for use in soft gelatin capsules
WO1993009229A1 (en) 1991-11-04 1993-05-13 Genetics Institute, Inc. Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
HUT63579A (en) * 1991-12-20 1993-09-28 Chinoin Gyogyszer Es Vegyeszet Process for producing double-phase pharmaceutical compositions suitable for treating diseases occurring during neurodegenerative processes
US5817336A (en) * 1993-04-02 1998-10-06 Orion-Yhtyma Oy Composition containing selegiline
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
AU689184B2 (en) 1993-12-07 1998-03-26 Genetics Institute, Llc BMP-12, BMP-13 and tendon-inducing compositions thereof
US5484608A (en) * 1994-03-28 1996-01-16 Pharmavene, Inc. Sustained-release drug delivery system
GB9426079D0 (en) * 1994-12-23 1995-02-22 Orion Yhtymae Oy A gelatine capsule
US6348208B1 (en) * 1995-01-13 2002-02-19 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US6299901B1 (en) 1995-01-13 2001-10-09 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US6319954B1 (en) 1995-01-13 2001-11-20 Somerset Pharmaceuticals, Inc. S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
US6033682A (en) 1995-01-13 2000-03-07 Somerset Pharmaceuticals, Inc. S(+) desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
DE19533772C1 (de) * 1995-09-12 1998-01-02 Hexal Ag Tacrin/Selegilin-Pflaster
DK0866691T4 (da) * 1995-11-06 2005-06-06 Somerset Pharmaceuticals Inc Medikamenter til sublingual og bukkal administration af selegilin
DE19716905C1 (de) * 1997-04-22 1998-08-27 Iip Inst Fuer Ind Pharmazie Fo Stabile, wäßrige Lösung auf der Grundlage von Selegilin und Vorrichtung zu ihrer Verabreichung
GB9715082D0 (en) * 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
EP1063981B1 (en) * 1998-03-16 2002-08-14 Somerset Pharmaceuticals, Inc. Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
WO2001034172A2 (en) * 1999-11-05 2001-05-17 Vela Pharmaceuticals Inc. Methods and compositions for treating reward deficiency syndrome
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
EP1399023B1 (en) 2001-06-01 2008-04-30 Wyeth COMPOSITIONS FOR SYSTEMIC ADMINISTRATION OF SEQUENCES ENCODING BONE MORPHOGENETIC PROTEINS& x9;
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
EP1487427A4 (en) * 2002-03-04 2006-01-18 Somerset Pharmaceuticals Inc METHODS FOR PREVENTING AND TREATING PERIPHERAL NEUROPATHY BY ADMINISTERING DESMETHYLSELEGILINE
US20050009862A1 (en) * 2003-04-25 2005-01-13 Sabounjian Luann Method for promoting uninterrupted sleep by administration of trospium chloride
DE10338174A1 (de) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
ATE357244T1 (de) 2003-09-12 2007-04-15 Wyeth Corp Injizierbare feste calciumphosphat-stäbe zur abgabe von osteogenen proteinen
US20050245617A1 (en) * 2004-01-29 2005-11-03 Meyerson Laurence R Methods and compositions for the treatment of CNS-related conditions
EP1734920A2 (en) * 2004-02-13 2006-12-27 Neuromolecular Inc. Combination of a nmda receptor antagonist and an mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP2623099A1 (en) 2004-11-24 2013-08-07 Neuromolecular Pharmaceuticals, Inc Composition and method for treating neurological disease
US20060264478A1 (en) * 2005-02-22 2006-11-23 Northwestern University Methods and compositions for modulating calcium channels
PL2982372T3 (pl) 2005-04-05 2020-12-28 Yale University Środki modulujące stężenie glutaminianu stosowane w leczeniu zaburzeń psychicznych
DK1874282T3 (da) 2005-04-06 2010-10-25 Adamas Pharmaceuticals Inc Fremgangsmåder og præparater til behandling af CNS lidelser
JP5648216B2 (ja) 2008-06-06 2015-01-07 ファーマ ツゥ ビー リミテッド パーキンソン病治療医薬組成物
EP2506709B2 (en) 2009-12-02 2019-10-09 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE314077C (es) *
AT314077B (de) * 1972-01-07 1974-03-25 Hurka Wilhelm Verfahren zur Herstellung eines neuen, gegen den Parkinsonismus wirksamen Kombinationspräparates
HU193662B (en) * 1983-12-20 1987-11-30 Chinoin Gyogyszer Es Vegyeszet Process for producing synergetic pharmaceutical composition of antidepressive aktivity

Also Published As

Publication number Publication date
AU7154187A (en) 1987-10-29
FI871668L (fi) 1987-10-17
HU197840B (en) 1989-06-28
DD259352A5 (de) 1988-08-24
GR3000707T3 (en) 1991-10-10
FI871668A0 (fi) 1987-04-15
IE60245B1 (en) 1994-06-15
HUT43789A (en) 1987-12-28
DK197787A (da) 1987-10-17
AU598533B2 (en) 1990-06-28
NO871581D0 (no) 1987-04-14
EP0241809B1 (de) 1990-08-08
ZA872690B (en) 1988-03-30
PT84684A (de) 1987-05-01
IE870973L (en) 1987-10-16
DK197787D0 (da) 1987-04-15
IL82216A0 (en) 1987-10-30
DE3764144D1 (de) 1990-09-13
FI871668A7 (fi) 1987-10-17
EP0241809A1 (de) 1987-10-21
PL265152A1 (en) 1988-07-07
ATE55245T1 (de) 1990-08-15
PT84684B (pt) 1989-12-29
DK168514B1 (da) 1994-04-11
CA1298200C (en) 1992-03-31
JPS62249923A (ja) 1987-10-30
US4812481A (en) 1989-03-14
NO871581L (no) 1987-10-19

Similar Documents

Publication Publication Date Title
ES2029805T3 (es) Procedimiento para preparar un producto que contiene amantadina y selegilina en asociacion sinergica.
AR243544A1 (es) Un procedimiento para la obtencion de un producto que comprende copolimero de etileno/propileno incorporado en una matriz de homopolimero o copolimero de propileno y producto obtenido con el.
SE8803486D0 (sv) Dosage form for treating cardiovascular diseases
MX170831B (es) Envase para barra con superficie de aplicacion
DE3869214D1 (de) Nadelloser injektor, insbesondere fuer die zahnmedizinische anwendung.
ES2055685T3 (es) Procedimiento para la obtencion de un medicamento que contiene ibuprofen.
ES8705762A1 (es) Procedimiento para preparar un agente analgesicamente activo a base de 2-amino-3-carboetoxiamino-6-(4-fluorobencilamino)-piridina y por lo menos un agente antiflogistico no esteroidal
ES2100046T3 (es) Composiciones antipireticas y analgesicas que contienen r-ketorolaco opticamente puro.
ES2070850T3 (es) Una composicion catalizadora homogenea con dos componentes y procedimiento para preparar alfa-olefinas lineales.
AU6871587A (en) Verapamil dosage form
ES8601698A1 (es) Procedimiento para producir preparados farmaceuticos a base de heparina y agentes tensioactivos.
ES2044849T3 (es) Un procedimiento para preparar un glicosido de flavona.
ES2051695T3 (es) Tratamiento de la trombosis que contiene un fibrinolitico y un analogo de carbaciclina.
ES2075255T3 (es) Separacion en enantiomeros de cimaterol.
MX14310A (es) Procedimiento para la preparacion de nuevos agentes antiarritmicos, producto obtenido y preparacion farmaceutica que lo incluye.
GR1001151B (el) Νεα xρηση θειορεδοξινης
ATE64300T1 (de) Wirkstoffe zur anwendung bei der behandlung von tumoren.
MX22522A (es) Procedimiento para la elaboracion de una composici on que contiene alfa-interferon y producto obten ido mediante el mismo.
AR228255A1 (es) Procedimiento para la produccion de una preparacion sinergistica que tiene una actividad analgesica y miotonolitica mejorada
ES2052670T3 (es) Utilizacion de derivados de 2-pirimidinil-1-piperazina.
ES2022501B3 (es) Procedimiento para preparar un aducto de lactato calcico y glicerol, y su empleo.
ATE69549T1 (de) Erzeugnisse, enthaltend gallopamil und prazosin.
ES2058601T3 (es) Formulaciones que contienen heparina.
ES2050655T3 (es) Aguja quirurgica oscura.
ES2022137B3 (es) Procedimiento de reciclaje de una tarjeta que consta de un compuesto, y tarjeta prevista para su reciclaje.